Wedbush analyst Liana Moussatos reiterated a Hold rating on Sangamo Biosciences (NASDAQ:SGMO) on Thursday, setting a price target of $11, which is approximately 4.84% below the present share price of $11.56.
Moussatos expects Sangamo Biosciences to post earnings per share (EPS) of -$0.29 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Sangamo Biosciences, with an average price target of $19.2.
The analysts price targets range from a high of $29 to a low of $11.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $25.8 million and a net profit of -$43.43 million. The company's market cap is $1.66 billion.
According to TipRanks.com, Wedbush analyst Liana Moussatos is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.0% and a 46.71% success rate.
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.